[Adeno-associated viruses (AAV)].
Recombinant adeno-associated virus derived vectors (rAAV) a thought to be a most promising candidates for gene therapy applications. Their nonpathogenic nature as well as the encouraging capability to infect both proliferating and non proliferating cells are advantages for gene therapy applications. Here, we summarize the potential mechanisms responsible for AAV maintenance and site-specific integration to human genome. The role of Rep proteins, inverted terminal repeats and p5 promotor sequences for chromosomal incorporation of AAV are discussed. Making the site-specific integrative recombinant AAV vectors for gene therapy seems to be closely dependent on the development of viral vectorology.
Małecki
Maciej
M
Zakład Biologii Komórki, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa. mahan@poczta.wp.pl
Woźniak
Agnieszka
A
Janik
Przemysław
P
D004279:DNA, Viral; D004268:DNA-Binding Proteins / Q000235:genetics*; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy; D015894:Genome, Human; D006801:Humans; D011401:Promoter Regions, Genetic; D014764:Viral Proteins / Q000235:genetics*
D004279:DNA, Viral; D004268:DNA-Binding Proteins; D014764:Viral Proteins